BioNTech's Founders to Spin Off Next-Gen mRNA Arm as Stock Sheds 22% and Revenue Guidance Stalls
Published on 06/24/2026 at 12:11 | Redaktion boerse-global.de
The announcement landed like a thunderbolt on March 10: Ugur Sahin and Özlem Türeci, the scientists who built BioNTech from a small Mainz startup into a global vaccine powerhouse, plan to leave the board by the end of 2026 and launch a separate biotechnology company focused on next-generation mRNA technologies. The news, released alongside the company’s fourth-quarter results, sent the Nasdaq-listed shares plunging roughly 22% in a single session.
Under the terms of the so-called founder deal, BioNTech will transfer certain rights and technologies to the new entity while retaining a minority stake. The parent company also secures future milestone payments and royalties. The final contracts are expected to be signed by the end of June 2026, after which Sahin and Türeci will remain in their executive roles until year-end before formally stepping down. The spin-off effectively splits early-stage platform innovation from late-stage commercial development, allowing BioNTech to concentrate fully on its oncology pipeline — a pivot that management believes is critical for long-term growth.
The market's reaction, however, was not solely driven by the leadership shake-up. BioNTech’s full-year 2025 results revealed deepening financial strain. Revenue for the year came in at €2.9 billion, a modest 4% increase from 2024, but the bottom line deteriorated sharply. The company swung from an adjusted net profit of €121.7 million in 2024 to an adjusted net loss of €117.1 million last year. Fourth-quarter revenue fell 24% to €907.4 million, dragged down by weaker demand for COVID-19 vaccines. The outlook for 2026 only added to the gloom: management guided for revenue of between €2.0 billion and €2.3 billion — below analyst expectations and underscoring the challenge of replacing pandemic-era sales.
Should investors sell immediately? Or is it worth buying BioNTech?
Competitive pressures are mounting from multiple fronts. At the BIO International Convention in San Diego, the Abu Dhabi Department of Health and Sanofi signed a memorandum of understanding to establish a joint vaccine innovation center focusing on AI-driven vaccine development and mRNA research. Meanwhile, South Korean contract manufacturer ST Pharm is expanding its mRNA and lipid-nanoparticle capacity, having secured four new contracts — some of which came from projects previously handled by Chinese suppliers that lost ground following the US Biosecure Act. Closer to home, Moderna has signaled interest in acquiring several of BioNTech’s German production sites as the company streamlines its manufacturing footprint to free up capital for costly oncology programs.
Despite the turmoil, BioNTech retains considerable financial firepower. The balance sheet as of May showed cash reserves of approximately €16.8 billion, and a multibillion-euro share buyback program continues to provide a floor for the stock. Yet technical indicators suggest persistent weakness. The shares recently closed at €79.70, slipping below the key 38-day moving average. At that level, the stock sits roughly 25% below its January high of €105.80 and is down over 3% year to date. The relative strength index of 52.5 points to neutral momentum — neither oversold nor overbought.
The next few weeks will be pivotal. The final signature on the founder contract must be affixed by June 30, clarifying the exact asset split and leadership structure of the remaining company. Beyond that, BioNTech’s credibility hinges on its ability to deliver early oncology milestones: the company plans to have 15 ongoing Phase 3 trials by the end of the year. Whether it can execute that ambitious pipeline without the two scientists who made it a household name is the question that will define the stock’s trajectory for the rest of 2026.
Ad
BioNTech Stock: New Analysis - 24 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
